An observational study in Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted, sponsored by UPECLIN HC FM Botucatu Unesp. Completed at 1 site in Brazil. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-03-20.
Sponsored by UPECLIN HC FM Botucatu Unesp · Observational
The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.
Chronic hepatitis C virus(HVC) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a large number of cases to complications such as cirrhosis, hepatic insufficiency and hepatocarcinoma. In Brazil, it is estimated three million estimated cases to 52 thousand reports. The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.
2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.
This study's enrollment of 100 is below the median of 250 across 687 observational studies indexed under Hepatitis A.
Browse Hepatitis A studies →UPECLIN HC FM Botucatu Unesp is the lead sponsor of 63 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
HVC patients attended in SAE e HD.
Exclusion Criteria:
HVC patients attended in SAE e HD.
Drug: pegylated-interferon, conventional-interferon, ribavirin
Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
Also known as: Pegasys, PegIntron, Ribavirin
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UPECLIN HC FM Botucatu Unesp